E
Eileen Baildam
Researcher at Boston Children's Hospital
Publications - 124
Citations - 5815
Eileen Baildam is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Arthritis & Childhood arthritis. The author has an hindex of 32, co-authored 119 publications receiving 4933 citations. Previous affiliations of Eileen Baildam include University of Manchester & National Health Service.
Papers
More filters
Journal ArticleDOI
Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.
Fabrizio De Benedetti,Hermine I. Brunner,Nicolino Ruperto,Andrew Kenwright,Stephen C. Wright,Inmaculada Calvo,Ruben Cuttica,Angelo Ravelli,Rayfel Schneider,Patricia Woo,Carine Wouters,Ricardo Machado Xavier,Lawrence S. Zemel,Eileen Baildam,Ruben Burgos-Vargas,Pavla Dolezalova,Stella Garay,Rosa Merino,Rik Joos,Alexei A. Grom,Nico M Wulffraat,Zbigniew Zuber,Francesco Zulian,Daniel J. Lovell,Alberto Martini +24 more
TL;DR: Tocilizumab was efficacious in severe, persistent systemic JIA and adverse events were common and included infection, neutropenia, and increased aminotransferase levels.
Journal ArticleDOI
Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling
Gillian I. Rice,Yoandris del Toro Duany,Yoandris del Toro Duany,Emma M. Jenkinson,Gabriella M A Forte,Beverley Anderson,Giada Ariaudo,Brigitte Bader-Meunier,Eileen Baildam,Roberta Battini,Michael W. Beresford,Manuela Casarano,Mondher Chouchane,Rolando Cimaz,Abigail Collins,Nuno Cordeiro,Russell C. Dale,Joyce Davidson,Liesbeth De Waele,Isabelle Desguerre,Laurence Faivre,Elisa Fazzi,Bertrand Isidor,Lieven Lagae,Andrew Latchman,Pierre Lebon,Chumei Li,John H. Livingston,Charles Marques Lourenço,Maria Margherita Mancardi,Alice Masurel-Paulet,Iain B. McInnes,Manoj P. Menezes,Cyril Mignot,James O'Sullivan,Simona Orcesi,Paolo Picco,Enrica Riva,Robert Robinson,Diana Rodriguez,Diana Rodriguez,Elisabetta Salvatici,Christiaan Scott,Marta Szybowska,John Tolmie,Adeline Vanderver,Catherine Vanhulle,José Pedro Vieira,Kate Webb,Robyn Whitney,Simon G. Williams,Lynne A. Wolfe,Sameer M. Zuberi,Sameer M. Zuberi,Sun Hur,Sun Hur,Yanick J. Crow +56 more
TL;DR: It is demonstrated that aberrant sensing of nucleic acids can cause immune upregulation and heterozygous mutations in the cytosolic double-stranded RNA receptor gene IFIH1 (also called MDA5) cause a spectrum of neuroimmunological features consistently associated with an enhanced interferon state.
Journal ArticleDOI
Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1.
Yanick J. Crow,Diana Chase,Johanna Lowenstein Schmidt,Marcin Szynkiewicz,Gabriella Forte,Hannah Gornall,Anthony Oojageer,Beverley Anderson,Amy Pizzino,Guy Helman,Mohamed S. Abdel-Hamid,Ghada M H Abdel-Salam,Sam Ackroyd,Alec Aeby,Guillermo Agosta,Catherine Albin,Stavit Allon-Shalev,Montse Arellano,Giada Ariaudo,Vijay Aswani,Riyana Babul-Hirji,Eileen Baildam,Nadia Bahi-Buisson,Kathryn Bailey,Christine Barnerias,Magalie Barth,Roberta Battini,Michael W. Beresford,Geneviève Bernard,Marika Bianchi,Thierry Billette de Villemeur,Edward Blair,Miriam Bloom,Alberto B. Burlina,Maria Luisa Carpanelli,Daniel R. Carvalho,Manuel Castro-Gago,Anna Cavallini,Cristina Cereda,Kate Chandler,David Chitayat,Abigail Collins,Concepcion Sierra Corcoles,Nuno Cordeiro,Giovanni Crichiutti,Lyvia Dabydeen,Russell C. Dale,Stefano D'Arrigo,Christian de Goede,Corinne De Laet,Liesbeth De Waele,Inés Denzler,Isabelle Desguerre,Koenraad Devriendt,Maja Di Rocco,Michael C Fahey,Elisa Fazzi,Colin D. Ferrie,António Figueiredo,Blanca Gener,Cyril Goizet,Nirmala Rani Gowrinathan,Kalpana Gowrishankar,Donncha Hanrahan,Bertrand Isidor,Bülent Kara,Nasaim Khan,Mary D. King,Edwin P. Kirk,Ram L. Kumar,Lieven Lagae,Pierre Landrieu,Heinz Lauffer,Vincent Laugel,Roberta La Piana,Ming K. Lim,Jean-Pierre Lin,Tarja Linnankivi,Mark T Mackay,Daphna Marom,Charles Marques Lourenço,Shane McKee,Isabella Moroni,Jenny Morton,Marie Laure Moutard,Kevin J. Murray,Rima Nabbout,Sheela Nampoothiri,Noemi Nunez-Enamorado,Patrick J. Oades,Ivana Olivieri,John R. Østergaard,Belén Pérez-Dueñas,Julie S. Prendiville,Venkateswaran Ramesh,Magnhild Rasmussen,Luc Régal,Federica Ricci,Marlène Rio,Diana Rodriguez,Agathe Roubertie,Elisabetta Salvatici,Karin Segers,Gyanranjan P. Sinha,Doriette Soler,Ronen Spiegel,Tommy Stödberg,Rachel Straussberg,Kathryn J. Swoboda,Mohnish Suri,Uta Tacke,Tiong Yang Tan,Johann te Water Naude,Keng Wee Teik,Maya Thomas,Marianne Till,Davide Tonduti,Enza Maria Valente,Rudy Van Coster,Marjo S. van der Knaap,Grace Vassallo,Raymon Vijzelaar,Julie Vogt,Geoffrey Wallace,Evangeline Wassmer,Hannah J. Webb,William P Whitehouse,Robyn Whitney,Maha S. Zaki,Sameer M. Zuberi,John H. Livingston,Flore Rozenberg,Pierre Lebon,Adeline Vanderver,Simona Orcesi,Gillian I. Rice +135 more
TL;DR: A robust relationship between mutations in all seven genes with increased type I interferon activity in cerebrospinal fluid and serum, and the increased expression of interferOn‐stimulated gene transcripts in peripheral blood is observed.
Journal ArticleDOI
A randomized, placebo‐controlled trial of infliximab plus methotrexate for the treatment of polyarticular‐course juvenile rheumatoid arthritis
Nicolino Ruperto,Daniel J. Lovell,Ruben Cuttica,Nick Wilkinson,Patricia Woo,Graciela Espada,Carine Wouters,Earl D. Silverman,Zsolt Balogh,Michael Henrickson,Maria Teresa Apaz,Eileen Baildam,Anders Fasth,Valeria Gerloni,Pekka Lahdenne,AM Prieur,Angelo Ravelli,Rotraud K. Saurenmann,M.L. Gamir,Nico M Wulffraat,László Maródi,Ross E. Petty,Rik Joos,Francesco Zulian,Deborah McCurdy,Barry L. Myones,K. Nagy,Peter Reuman,Ilona S. Szer,Suzanne Travers,A. Beutler,Greg Keenan,Jason Clark,Sudha Visvanathan,Adedigbo A. Fasanmade,Aparna Raychaudhuri,Alan M. Mendelsohn,Alberto Martini,Edward H. Giannini +38 more
TL;DR: Safety data indicated that the 6-mg/kg dose may provide a more favorable risk/benefit profile for infliximab in the treatment of juvenile rheumatoid arthritis, and achievement of the primary efficacy end point at 3 months did not differ significantly between inflIXimab-treated and placebo-treated patients.
Journal ArticleDOI
A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate.
Nicolino Ruperto,Kevin J. Murray,Valeria Gerloni,Nico M Wulffraat,Sheila Knupp Feitosa de Oliveira,Fernanda Falcini,Pavla Dolezalova,Maria Alessio,Ruben Burgos-Vargas,Fabrizia Corona,Richard Vesely,Helen E. Foster,Joyce Davidson,Francesco Zulian,Line Asplin,Eileen Baildam,Julia Garcia Consuegra,Huri Ozdogan,Rotraud K. Saurenmann,Rik Joos,Angela Pistorio,Pat Woo,Alberto Martini +22 more
TL;DR: This study shows that the plateau of efficacy of MTX in JIA is reached with parenteral administration of 15 mg/m(2)/week and that a further increase in dosage is not associated with any additional therapeutic benefit.